Antimicrobial resistance (AMR) results from a failure of medicines such as antibiotics to treat infections successfully. This leads to the emergence of micro-organisms or superbugs, which no longer respond to traditional antimicrobial medicines and can result in previously treatable infections becoming fatal.
AMR is a global health issue estimated to result in at least 10 million extra deaths a year globally by 2050 – more than the number of people who currently die from cancer.
In response to this public health threat, Imperial has established the Antimicrobial Research Collaborative (ARC@Imperial), which brings together scientists and clinicians from across the whole of the College to tackle the challenges of AMR through multidisciplinary, groundbreaking research and its translation into to new treatments, healthcare policy and practice.
Building on Imperial’s world-leading reputation in infection research, ARC@Imperial harnesses the expertise of more than 100 leading molecular bacteriologists, chemists, bioengineers, computational biologists, environmental scientists, epidemiologists and mathematicians with doctors, allied health professionals and policy makers across the AHSC and beyond.
Through collaborative work programmes around nine interdisciplinary themes, ARC@Imperial is delivering an exciting programme of research to improve patient care and population health.